ADIL Files New US Patent for AD04, Extending Protection to 2045

Adial Pharmaceuticals, Inc. announced the filing of a new U.S. utility patent application for AD04, its lead investigational therapeutic agent for Alcohol Use Disorder (AUD). If granted, the patent is expected to protect the company's core assets through at least 2045. The application includes a Request for Track One Prioritized examination to expedite the process, aiming to strengthen and extend the long-term value of its intellectual property portfolio and enhance strategic positioning for commercialization and licensing discussions.